双药联合治疗在 favourable-risk 晚期肾细胞癌中的系统评价与Meta分析
该系统评价与Meta分析纳入7项II/III期随机对照试验共1214例 favourable-risk 晚期肾细胞癌患者,比较一线双药联合治疗与舒尼替尼单药。
要点
- favourable-risk 晚期肾细胞癌一线双药联合较舒尼替尼单药无总生存获益。
- 双药联合无进展生存无显著获益,但排除ICI-ICI方案后PFS获益显著。
- 启动双药联合前需与患者充分讨论替代治疗选择。
核心结论
- 在 favourable-risk 晚期肾细胞癌患者中,双药联合治疗与舒尼替尼单药相比无总生存获益。
- 需更长随访以明确是否存在潜在总生存获益。
- 启动双药联合前应仔细讨论替代管理方案。
研究设计与样本
- 系统评价Medline、EMBASE和Cochrane Central Register of Controlled trials。
- 纳入一线、姑息性双药联合治疗 favourable-risk 晚期肾细胞癌的II/III期随机对照试验。
- 共纳入7项II/III期随机对照试验,N=1214。
- 采用逆方差随机效应模型进行Meta分析。
- 进行排除ICI-ICI联合方案的敏感性分析。
主要发现
- favourable-risk 组双药联合与舒尼替尼单药的总生存无显著差异(HR 0.96,95%CI 0.73-1.26,P=0.79)。
- 排除ICI-ICI方案的敏感性分析中总生存仍无显著获益(HR 0.99,95%CI 0.69-1.43,P=0.96)。
临床怎么用
- favourable-risk 晚期肾细胞癌患者一线选择双药联合需权衡缺乏总生存获益的证据。
- 与患者讨论时需说明双药联合在 favourable-risk 组的总生存和无进展生存结果。
- 排除ICI-ICI方案后无进展生存获益显著,可作为个体化决策参考。
局限性
- 需更长随访以明确潜在总生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To define the impact of first-line dual therapy involving immune checkpoint inhibitors (ICI) on survival outcomes in patients with advanced renal cell carcinoma (aRCC) of International Metastatic RCC Database Consortium favourable-risk. MATERIALS AND METHODS: Systematic review of Medline, EMBASE, and Cochrane Central Register of Controlled trials were conducted to select all phase II/III randomized clinical trials involving first-line, palliative-intent dual therapy in aRCC patients of favourable-risk. Inverse-variance with random-effects model was used for meta-analysis. Sensitivity analysis with exclusion of immune checkpoint inhibitors (ICI)-ICI combination was conducted. Study outcomes were overall survival (OS) and progression free survival (PFS). RESULTS: Seven phase II/III randomized controlled trials (N = 1214) were included in the meta-analysis. There were no significant OS differences detected in the favourable-risk group on dual therapy in comparison to sunitinib monotherapy (HR 0.96, 95%CI 0.73-1.26, P = .79). Sensitivity analysis also did not show significant OS benefit when excluding ICI-ICI regimen (HR 0.99, 95%CI 0.69-1.43, P = .96). PFS was not shown to have significant benefit for dual therapy in the favourable-risk group (HR 0.75, 95%CI 0.50-1.13, P = .17), but it met statistical significance when ICI-ICI regimen was excluded from the analysis (HR 0.63, 95%CI 0.50-0.79, P <.001). CONCLUSION: There was no OS benefit when comparing dual therapy vs sunitinib monotherapy in aRCC favourable-risk group. Longer follow-up would be required to definitively detect potential OS benefit, if any. Careful patient-clinician discussion of alternative management options are required prior to initiating dual-therapy in all aRCC favourable-risk group.
引用
- Kartolo A, Holstead RG, Duran I, et al. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. Urology. 2021. PMID: 34461142. doi:10.1016/j.urology.2021.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。